| Autor: |
Major A; Division of Hematology, University of Colorado School of Medicine, Aurora, CO 80045, USA., Porcu P; Division of Medical Oncology and Hematopoietic Stem Cell Transplantation, Thomas Jefferson University, Philadelphia, PA 19107, USA., Haverkos BM; Division of Hematology, University of Colorado School of Medicine, Aurora, CO 80045, USA. |
| Jazyk: |
angličtina |
| Zdroj: |
Cancers [Cancers (Basel)] 2023 Feb 21; Vol. 15 (5). Date of Electronic Publication: 2023 Feb 21. |
| DOI: |
10.3390/cancers15051366 |
| Abstrakt: |
Extranodal NK/T-cell lymphoma (ENKTL) is an aggressive extranodal non-Hodgkin lymphoma (NHL) with poor outcomes, particularly in advanced-stage and relapsed/refractory disease. Emerging research on molecular drivers of ENKTL lymphomagenesis by next-generation and whole genome sequencing has revealed diverse genomic mutations in multiple signaling pathways, with the identification of multiple putative targets for novel therapeutic agents. In this review, we summarize the biological underpinnings of newly-understood therapeutic targets in ENKTL with a focus on translational implications, including epigenetic and histone regulatory aberrations, activation of cell proliferation signaling pathways, suppression of apoptosis and tumor suppressor genes, changes in the tumor microenvironment, and EBV-mediated oncogenesis. In addition, we highlight prognostic and predictive biomarkers which may enable a personalized medicine approach toward ENKTL therapy. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
